History Repeating: Will US Stelara Settlements Follow Humira’s Lead?
Adalimumab Example Could Provide A Playbook For Settlements Over Ustekinumab Biosimilars
Years before Humira rivals hit the US market in 2023, a series of litigation settlements between biosimilar adalimumab developers and originator AbbVie provided a roadmap for a succession of date-certain launches this year. Now, similar settlements over Stelara between J&J and ustekinumab developers are starting to fall into place for 2025.
